News Releases

September 2021

September 16, 2021 9/16/2021 Takeda Continues to Advance Growth Strategy with Sale Of Non-Core Assets in Latin America

September 15, 2021 9/15/2021 Takeda’s EXKIVITY™ (mobocertinib) Approved by U.S. FDA as the First Oral Therapy Specifically Designed for Patients with EGFR Exon20 Insertion+ NSCLC

September 7, 2021 9/7/2021 Takeda to Manufacture and Provide 150 Million Doses of Novavax’ COVID-19 Vaccine Candidate to the Government of Japan

September 1, 2021 9/1/2021 Takeda Provides Update on Phase 3 PANTHER (Pevonedistat-3001) Trial

August 2021

August 6, 2021 8/6/2021 Takeda Updates its Q1 FY2021 Earnings Materials to Reflect Impact of Decision by the Irish Tax Appeals Commission Relating to Tax Assessment on Break Fee Shire Received from AbbVie

August 5, 2021 8/5/2021 Final Results from the Longest Hereditary Angioedema Study

August 1, 2021 8/1/2021 Takeda Receives Decision by the Irish Tax Appeals Commission Relating to Tax Assessment on Break Fee Shire Received from AbbVie

July 2021

July 30, 2021 7/30/2021 Takeda Delivers Solid First Quarter FY2021 Results, Positioning Company to Accelerate Topline Growth and Continued Pipeline Progress

July 29, 2021 7/29/2021 Takeda and Frazier Healthcare Partners Announce Collaboration to Launch HilleVax, Inc.